A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma

• DOI: 10.3892/ol.2023.13844
• Publication Date: 2023-04-28T12:37:15Z
• Authors: Jianghua Ding; Zhaohui Leng; Hong Gu; Xiang Jing
• Keywords: Regimen; Clinical endpoint

Rituximab is a widely used anti‑CD20 monoclonal antibody with high incidence of infusion‑related reactions (IRRs) during administration. Reducing the IRRs remains problematic in hematological practices. In present study, novel strategy prednisone pretreatment regimen was designed similar to combination rituximab, cyclophosphamide, epirubicin, vincristine and (R‑CHOP) aim exploring effect on rituximab patients diffuse large B‑cell lymphoma (DLBCL). A prospective, randomized (1:1) controlled study conducted three regional hospitals two groups (n=44 for each group): i) control group treated standard R‑CHOP‑like regimen; ii) receiving prednisone‑pretreatment, modified protocol newly diagnosed DLBCL. The primary endpoint assess as well association efficacy treatment. second involved clinical outcomes. total treatment significantly lower compared that (15.9 vs. 43.2%; P=0.0051). different grade (P=0.0053). total, 29.5% (26/88) experienced >1 IRR episode. pre‑treatment decreased 1st cycle P=0.0051) 2nd (6.8 27.3%; P=0.0107). overall response rate between (P>0.05). Median progression‑free survival median time were not statistically distinct (P=0.5244 P=0.5778, respectively). Grade ≥III toxicities mainly included vomiting nausea (<20%), leukopenia granulocytopenia alopecia (<25%). No death events reported. Apart from other adverse both groups. prednisone‑pretreatment incidences among This trial retrospectively registered Chinese Clinical Trial Registry (registration number, ChiCTR2300070327; date registration, 10 April 2023).